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Background: Germline genetic variants may influence pathways of tumor progression 
common to multiple cancer types. Here, we investigated the association between survival 
after colorectal cancer (CRC) diagnosis and 128 common genetic variants previously 
associated with prognosis in genome-wide association studies (GWAS) in different cancer 
types.  
Methods: We studied survival outcomes in a large well-documented, prospective, 
population-based cohort (5,675 CRC patients) with up to 20 years follow-up.   
Results: None of the 128 variants were significantly associated with overall or CRC-specific 
survival (p<5x10
-4
, Bonferroni-corrected threshold). We observed suggestive evidence 
(p<0.05) for eight variants (rs17026425, rs17057166, rs6854845, rs1728400, rs17693104, 
rs202280, rs6797464, rs823920) in all CRC and two variants (rs17026425, rs6854845) in 
rectal cancer that were concordant with previous reports.  
Conclusions: Given good statistical power (>0.80 for 75% of variants), this study indicates 
that most previously reported variants associated with cancer survival have limited influence 
on CRC prognosis.  
Impact: Although small effects cannot be excluded, clinically meaningful germline 








Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide(1). 
However, current knowledge on germline genetic influences over CRC prognosis is sparse. 
There is evidence that shared germline genetic basis exists across multiple cancer types in 
several key regulatory pathways of cancer pathogenesis(2) and progression(3). Previous 
genome-wide association studies (GWASs) have identified a number of genetic loci that 
might be associated with prognostic outcomes for various cancers. These genetic variants 
may also influence survival outcomes of CRC patients. Here, we report a large population-
based study investigating the effects of published GWAS-identified variants associated with 
cancer prognosis on CRC survival.   
 
Materials and Methods 
We searched the NHGRI-EBI GWAS Catalogue (https://www.ebi.ac.uk/gwas/ accessed in 
December 2018) to retrieve GWAS identified variants (p<5x10
-5
) associated with survival 
related traits for patients of any types of cancer. CRC patients with available information on 
age at diagnosis, sex, American Joint Committee on Cancer (AJCC) stage and GWAS data 
were included from the Study of Colorectal Cancer in Scotland (SOCCS). The MultiCentre 
Research Ethics committee for Scotland and other commitees approved the study and written 
informed consent was obtained from all participants.  Additional details on the study cohort 
and quality control measures on genotyping have been reported previously (4, 5).  CRC 
patients were prospectively followed up until death or censored on July 1st 2017. We 
evaluated overall survival (OS) and CRC-specific survival (CSS) as outcomes.  A Cox 
proportional hazards model was adopted to estimate the effect of each variant (under an 
additive genetic model) on survival outcomes adjusting for age, sex and AJCC stage. We also 
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performed stratified analyses by sex, AJCC stage and tumor site. With the type I error at α< 
5x10
-4
 (a Bonferroni corrected threshold), we estimated the study power for variants of 
various minor allele frequencies (MAF) and effect sizes using the method proposed by Owzar 
et al(6).    
 
Results 
A total of 5,675 CRC cases were included in this analysis and their basic characteristics are 
summarized in Table 1.  One-hundred and twenty-eight genetic variants (linkage 
disequilibrium r
2
<0.2) were identified from GWAS Catalogue (details presented in 
supplementary Table S1) and were included in the analysis.  Power calculation indicated a 
power of at least 0.80 to detect a hazard ratio (HR) of 1.25 for 75% of the included variants 
(MAF>0.1). Power estimates with various parameters are presented in supplementary Table 
S2.  In the overall analysis of all 5,675 CRC patients, none of the included variants were 
significantly associated with either OS or CSS (at p<0.0005).  We observed eight variants 
(rs17026425, rs17057166, rs6854845, rs1728400, rs17693104, rs202280, rs6797464, 
rs823920) with p<0.05 in the same direction of effects with previous findings (Table 2); of 
them, three variants (rs17026425, rs17057166, rs6854845) were previously reported to be 
associated with rectal cancer survival. In stratified analysis, the variant rs17026425 was 
statistically significantly associated with OS for male CRC patients (HR=1.37, 95% CI=1.15-
1.62, p=3.3x10
-4
). Additionally, we observed two variants to be associated at p<0.05 
(rs17026425, rs6854845) with OS in rectal cancer patients. No statistically significant 





Here, we studied all common variants previously reported to be associated with prognosis in 
different cancer types. Overall, our results do not support any associations between these 
variants and survival outcomes for CRC patients. There are some suggestive signals that may 
merit further investigation in even larger datasets.  For instance, we report a suggestive effect 
of rs17026425 in both overall and stratified analysis of rectal cancer patients, which concords 
with a previous GWAS(7). Of note, neither our study nor the previous GWAS detected 
association of this variant with colon cancer survival, indicating that this potential effect may 
be specific to rectal cancer. The variant is an intron variant of IQ motif containing M (IQCM) 
gene and is located in the binding region of JUN/JUND transcription factors, which manifest 
higher expression in CRC(8). The IQCM gene itself is highly expressed in testis only, making 
results restricted to males only in our study even more intriguing.   
Presented here the study has sufficient power to detect 75% of previously reported survival 
variants, but failed to do so.  Notably, 90% (19/21) of identified studies (Table S1) have 
sample size below 5,675 which is required to detect effect of genetic variants with MAF of 
10% and HR of 1.25, thus suggesting potential false positive association as well as 
overestimation of real effects in original studies (winner’s curse). Lack of pleiotropic and 
common effects across different cancers could also be behind the observed results, given the 
fact that variants reportedly associated with prognosis of other cancers except CRC showed 
mostly null effects in SOCCS.  Our findings show poor reproducibility of results in the field 
and a pressing need for collaborative efforts, so as to aggregate larger CRC cohorts with 
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Table 1 Summarized characteristics of the SOCCS cohort  
Basic characteristics  CRC cases (n=5,675) 
  Age at diagnosis (years)* 64.5(54.6-71.6) 
Sex  
 Male 3,235(57.0%) 
Female  2,440(43.0%) 
  Site 
 Colon  3,392(59.8%) 
Rectum 2,201(38.8%) 
Colon & rectum  16(0.3%) 
Unknown 66(1.2%) 
  AJCC stage  




  No. of all-cause deaths  1,918(33.8%) 
No. of CRC-related deaths  1,358(23.9%) 
*Median and quartiles in parenthesis.  
CRC, colorectal cancer; SOCCS, Study of Colorectal Cancer in Scotland; AJCC, American 





Table 2 Summarized results of genetic variants that are associated with CRC survival (p<0.05) in SOCCS  
Variant locus Gene 









Overall survival         
rs17026425 4q31.23 IQCM Rectal cancer(OS) 5.06 A 0.079 1.16(1.01-1.33) 0.039 1.00 
rs17057166 5q33.3 LINC01847 Rectal cancer(DFS) 5.56 T 0.088 1.14(1.00-1.29) 0.042 1.00 
rs6854845 4q13.3 Intergenic Rectal cancer(DFS) 3.31 T 0.119 1.14(1.01-1.29) 0.040 1.00 
rs1728400 16q24.1 Intergenic Breast cancer(OS) 0.80 A 0.330 0.93(0.87-0.99) 0.026 1.00 
rs17693104 10q23.1 SH2D4B Serous epithelial ovarian 
cancer(OS) 
1.65 T 0.348 1.08(1.01-1.15) 0.021 1.00 
rs11138220 9q21.31 Intergenic Rectal cancer(DFS) 2.76 G 0.131 0.88(0.79-0.98) 0.016 1.00 
          
CRC-specific survival         
rs17693104 10q23.1 SH2D4B Serous epithelial ovarian 
cancer(OS) 
1.65 T 0.348 1.09(1.01-1.17) 
 
0.031 1.00 
rs202280 8q21.13 intergenic Serous epithelial ovarian 
cancer(OS) 
2.00 G 0.038 1.14(1.02-1.26) 0.018 1.00 
rs6797464 3q26.2 MECOM Osteosarcoma(OS) 1.80 A 0.119 1.18(1.02-1.37) 0.030 1.00 
rs823920 9q31.1 Intergenic Pancreatic cancer(OS) 1.43 G 0.123 1.11(1.00-1.23) 0.042 1.00 
rs11138220 9q21.31 Intergenic Rectal cancer(DFS) 2.76 G 0.131 0.85(0.75-0.97) 0.016 1.00 
*Hazard ratios are estimated based on minor alleles.  
** Statistical power is estimated using originally reported effect sizes with type I error (α) at 0.0005.  
CRC, colorectal cancer; SOCCS, Study of Colorectal Cancer in Scotland; GWAS, genome-wide association studies; OS, overall survival; DFS, 
disease-free survival; MA, minor allele. MAF, minor allele frequency. 
